Immunotherapies

SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

All
FEATURED
ILCS
Webinars
Articles

       The Reading Room

Articles & Research

Nov 16 2026
RESEARCH
Immunotherapies

Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma

J. RemonN. GirardN. Reguart
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu
Oct 05 2026
RESEARCH
SCLCImmunotherapies

Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry

M. Hochmair
Oct 04 2026
RESEARCH
SCLCImmunotherapies

Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC

S. LiuM. ReckC. Rudin
Oct 02 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 26 2026
RESEARCH
Advanced NSCLCImmunotherapies

Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC

B. Ricciuti
Sep 15 2026
CONGRESS
Advanced NSCLCImmunotherapies

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

       The Reading Room

Articles & Research

Nov 16 2026
RESEARCH
Immunotherapies

Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma

J. RemonN. GirardN. Reguart
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu
Oct 05 2026
RESEARCH
SCLCImmunotherapies

Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry

M. Hochmair
Oct 04 2026
RESEARCH
SCLCImmunotherapies

Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC

S. LiuM. ReckC. Rudin
Oct 02 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 26 2026
RESEARCH
Advanced NSCLCImmunotherapies

Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC

B. Ricciuti
Sep 15 2026
CONGRESS
Advanced NSCLCImmunotherapies

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 13 2026
CONGRESS
Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months

Giannis Mountzios
Sep 13 2026
CONGRESS
Advanced NSCLCADCsImmunotherapies

EVOKE-03: sacituzumab govitecan plus pembrolizumab misses both primary endpoints

G. Mountzios
Sep 12 2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Sep 10 2026
INDUSTRY NEWS
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance improved OS in extensive-stage SCLC

Sep 09 2026
INDUSTRY NEWS
Advanced NSCLCImmunotherapies

HARMONi: ivonescimab plus chemotherapy gave 6.8 against 4.4 months PFS after EGFR TKI progression

Sep 08 2026
RESEARCH
Advanced NSCLCImmunotherapies

Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC

L. Hendriks
Sep 03 2026
INDUSTRY NEWS
Advanced NSCLCImmunotherapies

Akeso reports an OS benefit for ivonescimab over pembrolizumab in PD-L1-positive NSCLC

Sep 02 2026
RESEARCH
Advanced NSCLCImmunotherapies

AI-HOPE registry recruits 920 patients to build machine-learning models for metastatic NSCLC outcomes

R. FerraraL. Hendriks
Aug 27 2026
RESEARCH
Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara
Aug 25 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

Cleared ctDNA within weeks predicted longer survival on immunotherapy in a 109-patient study

P. Forde
Aug 21 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

A ctDNA tumour fraction of 5% or more marks who benefits from adding chemotherapy to checkpoint blockade

D. Planchard
Antonio Passaro
Aug 19 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC

T. CasconeP. FordeA. Passaro
Aug 13 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T

T. Cascone
Charles Rudin
Aug 09 2026
RESEARCH
Advanced NSCLCImmunotherapies

Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients

C. Rudin
Solange Peters
Aug 05 2026
RESEARCH
Advanced NSCLCImmunotherapies

AdvanTIG-301 closed early with 63 patients, leaving its stage III NSCLC comparisons descriptive

S. Peters
Charles Rudin
Aug 03 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab improved cough, breathlessness and chest pain against chemotherapy in DeLLphi-304

C. RudinG. Mountzios
Aug 02 2026
RESEARCH
Resectable NSCLCImmunotherapies

Five-year event-free survival was 49.9% with perioperative pembrolizumab against 26.5% in KEYNOTE-671

D. Rodríguez-AbreuM. Reck
Jul 15 2026
RESEARCH
Advanced NSCLCImmunotherapies

Proton pump inhibitors and antibiotics linked to reduced durvalumab benefit in unresectable stage III NSCLC

A. CortelliniD. PlanchardJ. NaidooJ. RemonB. Ricciuti